[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352110-105":59,"doc-detail-352110-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-oncogenic-kras-using-peptide-nucleic-acid-oligomers-attached-to-cell-penetrating-peptides","Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides","","Approximately 30% of tumors carry activating KRAS mutations, driving increased proliferation and contributing to cancers such as non-small cell lung cancer, colorectal adenocarcinoma, and pancreatic ductal adenocarcinoma (PDAC). This work reports peptide nucleic acid (PNA) oligomers designed to selectively bind KRAS G12D sequences, fused with novel cell-penetrating peptide regions (CPP-PNA-G12D), and evaluated in vitro and in cells. Binding selectivity was shown by electrophoretic mobility shift assays, while fluorescent microscopy and flow cytometry confirmed efficient cellular and nuclear uptake. Cell viability assays revealed a pronounced dose-response in KRAS G12D on-target cells with relative sparing of KRAS G12C off-target cells. The constructs inhibited PDAC cell lines and demonstrated activity in female Balb/c mice bearing patient-derived xenografts, supporting potential therapeutic KRAS-mutant selectivity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-oncogenic-kras-using-peptide-nucleic-acid-oligomers-attached-to-cell-penetrating-peptides/352110/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-oncogenic-kras-using-peptide-nucleic-acid-oligomers-attached-to-cell-penetrating-peptides/352110.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What KRAS mutation do the peptide nucleic acid oligomers target, and why is it important?","Question",{"text":112,"@type":113},"The PNA oligomers are designed to selectively bind the KRAS G12D mutation sequence. KRAS activation from mutations contributes to uncontrolled proliferation and is linked to multiple cancers including NSCLC, CRC, and PDAC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do the researchers confirm selective binding and cellular uptake of CPP-PNA-G12D?",{"text":117,"@type":113},"Electrophoretic mobility shift assays demonstrate in vitro binding and selectivity for KRAS G12D over wild-type KRAS and KRAS G12C. Fluorescent microscopy and flow cytometry show high-efficiency uptake in cells and nuclei.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports therapeutic potential against KRAS-mutant cancer cells?",{"text":121,"@type":113},"Dose-response viability assays show strong effects in on-target KRAS G12D expressing cells with relative sparing of KRAS G12C off-target cells. The constructs also show activity against a panel of PDAC cell lines and in patient-derived xenografts in mice.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352110,1790171017,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nTargeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides  \nJayati Mondal 1,2,3, Dennis Lam 1, Termika O. Alcindor 1,4,5,6, Mary E. Gerritsen 7,8, Tilmann M. Brotz 7,9, Jodi Kennedy 7, Bruce Rehlaender 7,9, Arthur J. Ross 7,10, Daniel E. Levy 7,11, Christopher A. Bonagura 12, William N. Lanzilotta 13, Frank McCormick 14,15, Jeffrey H. Rothman 7,16,17 and Andrew L. Wolfe 1,14,18,19,20, *  \nAcademic Editor: Elena Levantini  \nReceived: 6 July 2026  \nRevised: 31 July 2026  \nAccepted: 6 August 2026  \nPublished: 10 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Biological Sciences, Hunter College, City University of New York, New York, NY 10065, USA  \n2 Yalow Scholars Program, Hunter College, City University of New York, New York, NY 10065, USA  \n3 Damon Runyon Cancer Research Foundation, Scholars Program for Advancing Research and Knowledge, New York, NY 10006, USA  \n4 Maximizing Access to Research Careers Program, Hunter College, City University of New York, New York, NY 10065, USA  \n5 McNulty Scholars Program, Hunter College, City University of New York, New York, NY 10065, USA  \n6 Transfer to STEM Student Success Program, Hunter College, City University of New York, New York, NY 10065, USA  \n7 Oncogenuity, Inc., New York, NY 10014, USA  \n8 Gerritsen Consulting, San Mateo, CA 94402, USA  \n9 PharmaDirections, Cary, NC 27513, USA  \n10 Fortress Biotech, Waltham, MA 02453, USA  \n11 DEL BioPharma, LLC, San Mateo, CA 94402, USA  \n12 Art Robbins Instruments, Sunnyvale, CA 94089, USA  \n13 Department of Chemistry, University of Georgia, Athens, GA 30602, USA  \n14 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA  \n15 National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA  \n16 Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA  \n17 Herbert Irving Comprehensive Cancer Center, Department of Medicine, Columbia University School of Medicine, New York, NY 10032, USA  \n18 Weill Cornell Medicine, Department of Pharmacology, New York, NY 10065, USA  \n19 Molecular, Cellular, and Developmental Biology Ph.D. Subprogram, Graduate Center of the City University of New York, New York, NY 10016, USA  \n20 Biochemistry Ph.D. Program, Graduate Center of the City University of New York, New York, NY 10016, USA  \n* Correspondence: [awolfe@genectr.hunter.cuny.edu](awolfe@genectr.hunter.cuny.edu)  \nAbstract  \nApproximately 30% of tumors contain an activating mutation in the oncogene KRAS, leading to increased cell proliferation that often promotes non-small cell lung cancers, colorectal adenocarcinomas, pancreatic ductal adenocarcinomas (PDAC), and other cancers. Among the most common point mutations in KRAS is G12D, an example of an oncogenic sequence present in tumor cells but not normal cells. We developed peptide nucleic acid (PNA) oligomers that selectively bind KRAS G12D sequences and fused them with novel cell-penetrating peptide flanking regions (CPP-PNA-G12D) then evaluated them. Electrophoretic mobility shift assays demonstrated in vitro binding to and selectivity for KRAS G12D over wild-type KRAS and KRAS G12C. Cells and nuclei were able to uptake CPP-PNA-G12D at high efficiency as shown by fluorescent microscopy and flow cytometry. Cell viability assays showed a striking dose-response effect in on-target cells expressing KRAS G12D, while relatively sparing off-target cells expressing KRAS G12C. CPP-PNAG12D constructs were effective against a panel of PDAC cell lines and in female Balb/cmice bearing patient-derived xenografts. These results show promise for an enhanced PNA-delivery peptide conjugate strategy as a ","cbCaircEAMN8MU20","https://ap.wps.com/l/cbCaircEAMN8MU20","pdf",1348081,15,"English","# Abstract\n# Introduction\n## KRAS biology and mutation relevance\n## Limitations of existing KRAS inhibitors","[{\"question\":\"What KRAS mutation do the peptide nucleic acid oligomers target, and why is it important?\",\"answer\":\"The PNA oligomers are designed to selectively bind the KRAS G12D mutation sequence. KRAS activation from mutations contributes to uncontrolled proliferation and is linked to multiple cancers including NSCLC, CRC, and PDAC.\"},{\"question\":\"How do the researchers confirm selective binding and cellular uptake of CPP-PNA-G12D?\",\"answer\":\"Electrophoretic mobility shift assays demonstrate in vitro binding and selectivity for KRAS G12D over wild-type KRAS and KRAS G12C. Fluorescent microscopy and flow cytometry show high-efficiency uptake in cells and nuclei.\"},{\"question\":\"What evidence supports therapeutic potential against KRAS-mutant cancer cells?\",\"answer\":\"Dose-response viability assays show strong effects in on-target KRAS G12D expressing cells with relative sparing of KRAS G12C off-target cells. The constructs also show activity against a panel of PDAC cell lines and in patient-derived xenografts in mice.\"}]","Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides | PDF",1790097742,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1985bb2adae85383048fc341833abd44.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05cd6968d95bfc1a7910a8a4a646d6a9.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c13d82d8667e47f528a972b9e2da26a.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f732c5f0db4c8543076b3bc5a177b9a.webp",980,1385]